The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 May 2017 07:00

RNS Number : 6026F
Scancell Holdings Plc
19 May 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Scancell Holdings PLC

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc

Legal & General (Unit Trust Managers) Limited (UTM)

Legal & General Investment Management Limited (LGIM)

4. Full name of shareholder(s)  (if different from 3.):

n/a

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

16 May 2017

6. Date on which issuer notified:

18 May 2017

7. Threshold(s) that is/are crossed orreached:

 

 

 

LGIM (Above 5%) UTM (Above 5%)

 

 

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD GBP0.001

 

(LGIM)

 

First notification under DTR Sourcebook

 

 16,000,000

-

16,000,000

-

5.13%

ORD GBP0.001

 

(UTM)

 

First notification under DTR Sourcebook

16,000,000

-

16,000,000

-

5.13%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 16,000,000

 

LGIM

 

5.13%

 

 16,000,000

 

UTM

 

5.13%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 16,000,000 -5.13% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 16,000,000 - 5.13% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 16,000,000 - 5.13% = Total Position)

Legal & General (Unit Trust Managers) Limited ( 16,000,000 - 5.13% = UTM)

Legal & General Group Plc (Direct) (L&G)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance (Pensions Management) Limited (PMC)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  312,058,098

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFFREVITLID
Date   Source Headline
15th May 20147:30 amRNSPresents latest SCIB1 data at ASCO
9th May 20148:30 amRNSDirectorate Change
1st May 20147:00 amRNSDr Sally Adams to Join as Development Director
4th Apr 20147:00 amRNSScancell to present SCIB1 at AACR
21st Mar 20147:00 amRNS8mg Higher Dose SCIB1 Study On Track
18th Feb 20147:00 amRNSPublication of Moditope Patent
11th Feb 20147:00 amRNSSCIB1 Granted FDA Orphan Drug Status
10th Feb 20144:43 pmRNSHolding(s) in Company
6th Jan 20147:00 amRNSNottingham Technology Grant
16th Dec 20137:00 amRNSNottingham Trent University Cancer Protein Study
12th Dec 20137:00 amRNSDNA ImmunoBody Patent Granted in Japan
11th Dec 20137:00 amRNSDirector/PDMR Shareholding
9th Dec 20137:00 amRNSNew data for SCIB1 in metastatic melanoma
9th Dec 20137:00 amRNSHalf Yearly Report
18th Nov 20137:00 amRNSRe Agreement with Ichor
1st Nov 20134:56 pmRNSAGM Statement
22nd Oct 20138:00 amRNSDirector/PDMR Shareholding
14th Oct 201310:10 amRNSHolding(s) in Company
8th Oct 20132:54 pmRNSNotice of AGM
1st Oct 20137:00 amRNSInvestor Update
24th Sep 20137:00 amRNSInvestor Update Agenda
10th Sep 20133:06 pmRNSInvestor Day
3rd Sep 20137:00 amRNSDNA ImmunoBody Patent Granted in first market
20th Aug 20137:00 amRNSInclusion on Frankfurt Stock Exchange
12th Aug 20135:16 pmRNSDirector/PDMR Shareholding
8th Aug 20133:15 pmRNSHolding(s) in Company
5th Aug 20132:17 pmRNSHolding(s) in Company
1st Aug 201311:39 amRNSResult of General Meeting
26th Jul 20137:00 amRNSResult of Open Offer
23rd Jul 20137:00 amRNSDirector/PDMR Shareholding
19th Jul 20134:40 pmRNSSecond Price Monitoring Extn
19th Jul 20134:35 pmRNSPrice Monitoring Extension
12th Jul 20137:00 amRNSResearch Update
10th Jul 201310:55 amRNSAnnual Financial Report
9th Jul 20137:00 amRNSProposed Firm Placing and Open Offer
9th Jul 20137:00 amRNSFinal Results
9th Apr 20137:00 amRNSAppointment of Non-Executive Director
14th Mar 20137:00 amRNSRe: The Journal of Clinical Investigation Paper
27th Feb 20132:00 pmRNSDirectorate Change
6th Feb 20137:00 amRNSImmunoBody patent approved for grant in Japan
31st Jan 20137:00 amRNSHalf Yearly Report
29th Jan 20137:00 amRNSUpdate on patient recruitment in clinical trial
12th Dec 20127:00 amRNSDirectorate Change
12th Dec 20127:00 amRNSSCIB1 Trial-Higher Dose Allowed in Phase 1/2 Trial
6th Dec 20127:00 amRNSUpdate on SCIB1 Phase 1/2 clinical trial
3rd Dec 20129:30 amRNSHolding(s) in Company
7th Nov 20124:02 pmRNSResult of AGM
12th Oct 20127:00 amRNSFinal Results
8th Oct 201210:43 amRNSHolding(s) in Company
8th Oct 201210:43 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.